Development of disruptive treatment method
through therapeutic aerosols
Based in Germany, the company develops medical devices and drug formulations for the treatment of peritoneal cancer and has received several awards worldwide. Furthermore, the team of experts offers contract research for clinics and pharmaceutical companies.
First closing €1M for certification and approval
Second closing €3M for phase 1 and 2 clinical trials
Third Closing €6M for Phase 3 pivotal study and regulatory approval in Europe and the US